Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation

Shih Huang Lee, Shih Ann Chen, Ching Tai Tai, Chern En Chiang, Zu Chi Wen, Yi Jen Chen, Wen Chung Yu, Jin Long Huang, Ann Ning Fong, Jun Jack Cheng, Mau Song Chang

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system. In the oral propafenone group (n = 41), 2 patients (5%) discontinued therapy because of gastrointestinal discomfort in 1 and dizziness in the other. Thirty-one (79%) of the 39 patients who continued the treatment had effective response to oral propafenone (>75% reduction of symptomatic arrhythmic attacks) on a mean dose of 663 ± 99 mg/day with a decrease in attack frequency from 10 ± 3 to 2 ± 1 times per week. In the oral sotalol group (n = 38), 4 patients (11%) discontinued treatment because of dizziness in 2 and symptomatic bradycardia in 2. Twenty-six of the 34 patients (76%) who continued the treatment had effective response to oral sotalol on a mean dose of 200 ± 57 mg/day with a decrease in attack frequency from 11 ± 3 to 2 ± 1 times per week. Comparisons of the results between propafenone and sotalol groups showed a similar incidence of intolerable (2 of 41 vs 4 of 38, p = 0.42) and tolerable side effects (10 of 39 vs 8 of 34, p = 1.0). The attack frequency at baseline (11 ± 3 vs 10 ± 4 times per week, p = 0.23) and after treatment (3 ± 1 vs 3 ± 2 times per week, p = 0.85) did not differ significantly between the 2 groups. The incidence of effective response to drugs was also similar (31 of 39 vs 26 of 34, p = 0.78). Furthermore, the decrease of symptom scores (-32 ± 8% vs 29 ± 7%, p = 0.18) and percentage decrease of ventricular rate (-15 ± 4% vs - 18 ± 4%, p = 0.10) during AF were also similar between the 2 groups. In conclusion, oral propafenone and sotalol are equally effective and safe in preventing attacks and alleviating symptoms of paroxysmal AF.

Original languageEnglish
Pages (from-to)905-908
Number of pages4
JournalAmerican Journal of Cardiology
Volume79
Issue number7
DOIs
Publication statusPublished - Apr 1 1997
Externally publishedYes

Fingerprint

Propafenone
Sotalol
Atrial Fibrillation
Dizziness
Therapeutics
Incidence
Bradycardia
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. / Lee, Shih Huang; Chen, Shih Ann; Tai, Ching Tai; Chiang, Chern En; Wen, Zu Chi; Chen, Yi Jen; Yu, Wen Chung; Huang, Jin Long; Fong, Ann Ning; Cheng, Jun Jack; Chang, Mau Song.

In: American Journal of Cardiology, Vol. 79, No. 7, 01.04.1997, p. 905-908.

Research output: Contribution to journalArticle

Lee, Shih Huang ; Chen, Shih Ann ; Tai, Ching Tai ; Chiang, Chern En ; Wen, Zu Chi ; Chen, Yi Jen ; Yu, Wen Chung ; Huang, Jin Long ; Fong, Ann Ning ; Cheng, Jun Jack ; Chang, Mau Song. / Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. In: American Journal of Cardiology. 1997 ; Vol. 79, No. 7. pp. 905-908.
@article{b826ec16bac84b34aad3dfb136d43cc6,
title = "Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation",
abstract = "The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system. In the oral propafenone group (n = 41), 2 patients (5{\%}) discontinued therapy because of gastrointestinal discomfort in 1 and dizziness in the other. Thirty-one (79{\%}) of the 39 patients who continued the treatment had effective response to oral propafenone (>75{\%} reduction of symptomatic arrhythmic attacks) on a mean dose of 663 ± 99 mg/day with a decrease in attack frequency from 10 ± 3 to 2 ± 1 times per week. In the oral sotalol group (n = 38), 4 patients (11{\%}) discontinued treatment because of dizziness in 2 and symptomatic bradycardia in 2. Twenty-six of the 34 patients (76{\%}) who continued the treatment had effective response to oral sotalol on a mean dose of 200 ± 57 mg/day with a decrease in attack frequency from 11 ± 3 to 2 ± 1 times per week. Comparisons of the results between propafenone and sotalol groups showed a similar incidence of intolerable (2 of 41 vs 4 of 38, p = 0.42) and tolerable side effects (10 of 39 vs 8 of 34, p = 1.0). The attack frequency at baseline (11 ± 3 vs 10 ± 4 times per week, p = 0.23) and after treatment (3 ± 1 vs 3 ± 2 times per week, p = 0.85) did not differ significantly between the 2 groups. The incidence of effective response to drugs was also similar (31 of 39 vs 26 of 34, p = 0.78). Furthermore, the decrease of symptom scores (-32 ± 8{\%} vs 29 ± 7{\%}, p = 0.18) and percentage decrease of ventricular rate (-15 ± 4{\%} vs - 18 ± 4{\%}, p = 0.10) during AF were also similar between the 2 groups. In conclusion, oral propafenone and sotalol are equally effective and safe in preventing attacks and alleviating symptoms of paroxysmal AF.",
author = "Lee, {Shih Huang} and Chen, {Shih Ann} and Tai, {Ching Tai} and Chiang, {Chern En} and Wen, {Zu Chi} and Chen, {Yi Jen} and Yu, {Wen Chung} and Huang, {Jin Long} and Fong, {Ann Ning} and Cheng, {Jun Jack} and Chang, {Mau Song}",
year = "1997",
month = "4",
day = "1",
doi = "10.1016/S0002-9149(97)00025-8",
language = "English",
volume = "79",
pages = "905--908",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation

AU - Lee, Shih Huang

AU - Chen, Shih Ann

AU - Tai, Ching Tai

AU - Chiang, Chern En

AU - Wen, Zu Chi

AU - Chen, Yi Jen

AU - Yu, Wen Chung

AU - Huang, Jin Long

AU - Fong, Ann Ning

AU - Cheng, Jun Jack

AU - Chang, Mau Song

PY - 1997/4/1

Y1 - 1997/4/1

N2 - The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system. In the oral propafenone group (n = 41), 2 patients (5%) discontinued therapy because of gastrointestinal discomfort in 1 and dizziness in the other. Thirty-one (79%) of the 39 patients who continued the treatment had effective response to oral propafenone (>75% reduction of symptomatic arrhythmic attacks) on a mean dose of 663 ± 99 mg/day with a decrease in attack frequency from 10 ± 3 to 2 ± 1 times per week. In the oral sotalol group (n = 38), 4 patients (11%) discontinued treatment because of dizziness in 2 and symptomatic bradycardia in 2. Twenty-six of the 34 patients (76%) who continued the treatment had effective response to oral sotalol on a mean dose of 200 ± 57 mg/day with a decrease in attack frequency from 11 ± 3 to 2 ± 1 times per week. Comparisons of the results between propafenone and sotalol groups showed a similar incidence of intolerable (2 of 41 vs 4 of 38, p = 0.42) and tolerable side effects (10 of 39 vs 8 of 34, p = 1.0). The attack frequency at baseline (11 ± 3 vs 10 ± 4 times per week, p = 0.23) and after treatment (3 ± 1 vs 3 ± 2 times per week, p = 0.85) did not differ significantly between the 2 groups. The incidence of effective response to drugs was also similar (31 of 39 vs 26 of 34, p = 0.78). Furthermore, the decrease of symptom scores (-32 ± 8% vs 29 ± 7%, p = 0.18) and percentage decrease of ventricular rate (-15 ± 4% vs - 18 ± 4%, p = 0.10) during AF were also similar between the 2 groups. In conclusion, oral propafenone and sotalol are equally effective and safe in preventing attacks and alleviating symptoms of paroxysmal AF.

AB - The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system. In the oral propafenone group (n = 41), 2 patients (5%) discontinued therapy because of gastrointestinal discomfort in 1 and dizziness in the other. Thirty-one (79%) of the 39 patients who continued the treatment had effective response to oral propafenone (>75% reduction of symptomatic arrhythmic attacks) on a mean dose of 663 ± 99 mg/day with a decrease in attack frequency from 10 ± 3 to 2 ± 1 times per week. In the oral sotalol group (n = 38), 4 patients (11%) discontinued treatment because of dizziness in 2 and symptomatic bradycardia in 2. Twenty-six of the 34 patients (76%) who continued the treatment had effective response to oral sotalol on a mean dose of 200 ± 57 mg/day with a decrease in attack frequency from 11 ± 3 to 2 ± 1 times per week. Comparisons of the results between propafenone and sotalol groups showed a similar incidence of intolerable (2 of 41 vs 4 of 38, p = 0.42) and tolerable side effects (10 of 39 vs 8 of 34, p = 1.0). The attack frequency at baseline (11 ± 3 vs 10 ± 4 times per week, p = 0.23) and after treatment (3 ± 1 vs 3 ± 2 times per week, p = 0.85) did not differ significantly between the 2 groups. The incidence of effective response to drugs was also similar (31 of 39 vs 26 of 34, p = 0.78). Furthermore, the decrease of symptom scores (-32 ± 8% vs 29 ± 7%, p = 0.18) and percentage decrease of ventricular rate (-15 ± 4% vs - 18 ± 4%, p = 0.10) during AF were also similar between the 2 groups. In conclusion, oral propafenone and sotalol are equally effective and safe in preventing attacks and alleviating symptoms of paroxysmal AF.

UR - http://www.scopus.com/inward/record.url?scp=0030948892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030948892&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)00025-8

DO - 10.1016/S0002-9149(97)00025-8

M3 - Article

VL - 79

SP - 905

EP - 908

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -